Marla C. Dubinsky, MD / David T. Rubin, MD - TNF Inhibitors in Inflammatory Bowel Disease: How Can We Realize Opportunities to Optimize Clinical and Patient Outcomes?

Visit https://www.peervoice.com/XAD860 to view the entire programme with slides. After completing “Marla C. Dubinsky, MD / David T. Rubin, MD - TNF Inhibitors in Inflammatory Bowel Disease: How Can We Realize Opportunities to Optimize Clinical and Patient Outcomes?”, participants will be able to: Recall the evidence of the impact of tumor necrosis factor (TNF) inhibitors on endoscopic outcomes in patients with inflammatory bowel disease (IBD); Use clinical data to illustrate the potential benefits of early intervention with; TNF inhibitors in patients with IBD; Explain the importance of maintaining a steady, stable serum drug level during maintenance treatment of IBD with a TNF inhibitor; and Apply recommended approaches for effective and safe management of patients receiving TNF inhibitor-based maintenance therapy that optimizes both clinical and patient outcomes.